371 related articles for article (PubMed ID: 25512330)
1. Using the BioAssay Ontology for analyzing high-throughput screening data.
Zander Balderud L; Murray D; Larsson N; Vempati U; Schürer SC; Bjäreland M; Engkvist O
J Biomol Screen; 2015 Mar; 20(3):402-15. PubMed ID: 25512330
[TBL] [Abstract][Full Text] [Related]
2. Formalization, annotation and analysis of diverse drug and probe screening assay datasets using the BioAssay Ontology (BAO).
Vempati UD; Przydzial MJ; Chung C; Abeyruwan S; Mir A; Sakurai K; Visser U; Lemmon VP; Schürer SC
PLoS One; 2012; 7(11):e49198. PubMed ID: 23155465
[TBL] [Abstract][Full Text] [Related]
3. Assessing HTS performance using BioAssay Ontology: screening and analysis of a bacterial phospho-N-acetylmuramoyl-pentapeptide translocase campaign.
Moberg A; Zander Balderud L; Hansson E; Boyd H
Assay Drug Dev Technol; 2014; 12(9-10):506-13. PubMed ID: 25415593
[TBL] [Abstract][Full Text] [Related]
4. Rethinking molecular similarity: comparing compounds on the basis of biological activity.
Petrone PM; Simms B; Nigsch F; Lounkine E; Kutchukian P; Cornett A; Deng Z; Davies JW; Jenkins JL; Glick M
ACS Chem Biol; 2012 Aug; 7(8):1399-409. PubMed ID: 22594495
[TBL] [Abstract][Full Text] [Related]
5. BioAssay ontology annotations facilitate cross-analysis of diverse high-throughput screening data sets.
Schürer SC; Vempati U; Smith R; Southern M; Lemmon V
J Biomol Screen; 2011 Apr; 16(4):415-26. PubMed ID: 21471461
[TBL] [Abstract][Full Text] [Related]
6. BioAssay Ontology (BAO): a semantic description of bioassays and high-throughput screening results.
Visser U; Abeyruwan S; Vempati U; Smith RP; Lemmon V; Schürer SC
BMC Bioinformatics; 2011 Jun; 12():257. PubMed ID: 21702939
[TBL] [Abstract][Full Text] [Related]
7. Biodiversity of small molecules--a new perspective in screening set selection.
Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
[TBL] [Abstract][Full Text] [Related]
8. An efficient method for the detection and elimination of systematic error in high-throughput screening.
Makarenkov V; Zentilli P; Kevorkov D; Gagarin A; Malo N; Nadon R
Bioinformatics; 2007 Jul; 23(13):1648-57. PubMed ID: 17463024
[TBL] [Abstract][Full Text] [Related]
9. Public Domain HTS Fingerprints: Design and Evaluation of Compound Bioactivity Profiles from PubChem's Bioassay Repository.
Helal KY; Maciejewski M; Gregori-Puigjané E; Glick M; Wassermann AM
J Chem Inf Model; 2016 Feb; 56(2):390-8. PubMed ID: 26898267
[TBL] [Abstract][Full Text] [Related]
10. Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review.
Shun TY; Lazo JS; Sharlow ER; Johnston PA
J Biomol Screen; 2011 Jan; 16(1):1-14. PubMed ID: 21160066
[TBL] [Abstract][Full Text] [Related]
11. Using information from historical high-throughput screens to predict active compounds.
Riniker S; Wang Y; Jenkins JL; Landrum GA
J Chem Inf Model; 2014 Jul; 54(7):1880-91. PubMed ID: 24933016
[TBL] [Abstract][Full Text] [Related]
12. Non-stoichiometric inhibition in integrated lead finding - a literature review.
Klumpp M
Expert Opin Drug Discov; 2016; 11(2):149-62. PubMed ID: 26653534
[TBL] [Abstract][Full Text] [Related]
13. [High-throughput Screening Technology for Selective Inhibitors of Transporters and Its Application in Drug Discovery].
Motoyaji T
Yakugaku Zasshi; 2021; 141(4):511-515. PubMed ID: 33790118
[TBL] [Abstract][Full Text] [Related]
14. Latent hit series hidden in high-throughput screening data.
Varin T; Didiot MC; Parker CN; Schuffenhauer A
J Med Chem; 2012 Feb; 55(3):1161-70. PubMed ID: 22185196
[TBL] [Abstract][Full Text] [Related]
15. PubChem BioAssay: A Decade's Development toward Open High-Throughput Screening Data Sharing.
Wang Y; Cheng T; Bryant SH
SLAS Discov; 2017 Jul; 22(6):655-666. PubMed ID: 28346087
[TBL] [Abstract][Full Text] [Related]
16. Compound set enrichment: a novel approach to analysis of primary HTS data.
Varin T; Gubler H; Parker CN; Zhang JH; Raman P; Ertl P; Schuffenhauer A
J Chem Inf Model; 2010 Dec; 50(12):2067-78. PubMed ID: 21073183
[TBL] [Abstract][Full Text] [Related]
17. Making every SAR point count: the development of Chemistry Connect for the large-scale integration of structure and bioactivity data.
Muresan S; Petrov P; Southan C; Kjellberg MJ; Kogej T; Tyrchan C; Varkonyi P; Xie PH
Drug Discov Today; 2011 Dec; 16(23-24):1019-30. PubMed ID: 22024215
[TBL] [Abstract][Full Text] [Related]
18. Smart screening: approaches to efficient HTS.
Engels MF; Venkatarangan P
Curr Opin Drug Discov Devel; 2001 May; 4(3):275-83. PubMed ID: 11560058
[TBL] [Abstract][Full Text] [Related]
19. Computational Analysis and In silico Predictive Modeling for Inhibitors of PhoP Regulon in S. typhi on High-Throughput Screening Bioassay Dataset.
Kaur H; Ahmad M; Scaria V
Interdiscip Sci; 2016 Mar; 8(1):95-101. PubMed ID: 26298582
[TBL] [Abstract][Full Text] [Related]
20. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
